In the 2016 EpiPen controversy, by approximately what percentage did Mylan increase the price of this life-saving epinephrine auto-injector between 2009 and 2016?

In 2016, a major pharmaceutical company faced tremendous backlash for a controversial pricing strategy on a life-saving medical device. The incident became a flashpoint in debates about pharmaceutical ethics, pricing transparency, and patient access to essential medications. This case study highlights the complex balance between profit motives and public health responsibilities in the medical product industry.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Around 100% (doubled in price)
Around 250% (3.5x increase)
Around 500% (6x increase)
Around 1000% (11x increase)